Response to Savolitinib in a Patient with Advanced Poorly Differentiated Lung Carcinoma Positive for a Novel EML4-MET Gene Fusion.

Ganlu OuyangPei ShuYinyin XueFeng LuoYan Li

Published in: OncoTargets and therapy (2024)

This case uncovers a new type of MET fusion and expands the range of potential MET fusion targets in NSCLC. The patient responded to savolitinib, suggesting a reference basis for the treatment of similar cases with EML4-MET fusion in the future. Additional research is warranted to assess the biological significance of the EML4-MET fusion in NSCLC.

Keyphrases

tyrosine kinase
small cell lung cancer
case report
advanced non small cell lung cancer
epidermal growth factor receptor
genome wide
gene expression
transcription factor
combination therapy
human health